Stakeholders Ask FDA to Clarify Guidance on ‘Indications and Usage’ in Labeling

Drug Industry Daily
A A
In comments on the FDA’s draft guidance on the Usage and Indication sections of drug labeling, Novartis and Pfizer asked the agency to clarify its thinking on limitations of use.

To View This Article:

Login

Subscribe To Drug Industry Daily